Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 67
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for PTGX

Stock Name	Protagonist Therapeutics Inc
Ticker	PTGX(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US74366E1029

Show aggregate PTGX holdings

News associated with PTGX

Protagonist Therapeutics (NASDAQ:PTGX) Now Covered by Barclays: Barclays began coverage on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $72.00 price target on the stock. Several other research firms have also issued reports on PTGX. JMP Securities increased their target price on […] - 2025-09-19 02:36:48
HC Wainwright Reiterates Buy Rating for Protagonist Therapeutics (NASDAQ:PTGX): Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They currently have a $80.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 28.74% from the stock’s previous close. A number of other […] - 2025-09-19 02:36:47
Protagonist Therapeutics (NASDAQ:PTGX) Upgraded at Leerink Partnrs: Leerink Partnrs upgraded shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) to a strong-buy rating in a research report released on Friday morning,Zacks.com reports. Leerink Partnrs also issued estimates for Protagonist Therapeutics’ Q3 2025 earnings at ($0.60) EPS, Q4 2025 earnings at ($0.61) EPS and FY2025 earnings at ($1.95) EPS. A number of other analysts […] - 2025-09-15 02:47:57
We Did The Math IJR Can Go To $133: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-28 09:18:11
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Mutual of America Capital Management LLC: Mutual of America Capital Management LLC decreased its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 3.9% during the 1st quarter, Holdings Channel.com reports. The firm owned 8,679 shares of the company’s stock after selling 348 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Protagonist Therapeutics were […] - 2025-08-13 05:45:10
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Rating of “Buy” by Analysts: Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) has been given a consensus recommendation of “Buy” by the nine research firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation […] - 2025-08-08 04:42:56
Jefferies Financial Group Inc. Sells 857,602 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Jefferies Financial Group Inc. lessened its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 57.6% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 631,893 shares of the company’s stock after selling 857,602 shares during the period. Jefferies Financial Group Inc.’s holdings in Protagonist Therapeutics were worth $30,558,000 as of […] - 2025-08-01 05:38:53
Royce & Associates LP Buys New Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Royce & Associates LP bought a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 12,255 shares of the company’s stock, valued at approximately $593,000. A number of other hedge funds […] - 2025-07-30 04:49:05
XSMO's Underlying Holdings Could Mean 15% Gain Potential: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-07-28 08:27:31
Dinesh V. Ph D. Patel Sells 12,859 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock: Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) CEO Dinesh V. Ph D. Patel sold 12,859 shares of the company’s stock in a transaction dated Monday, July 21st. The shares were sold at an average price of $54.86, for a total value of $705,444.74. Following the sale, the chief executive officer owned 570,603 shares in […] - 2025-07-25 06:28:57
Dinesh V. Ph D. Patel Sells 17,520 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock: Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) CEO Dinesh V. Ph D. Patel sold 17,520 shares of the stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $54.79, for a total transaction of $959,920.80. Following the transaction, the chief executive officer owned 531,018 shares in the […] - 2025-07-25 05:42:54
Massachusetts Financial Services Co. MA Sells 723 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Massachusetts Financial Services Co. MA trimmed its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 2.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 31,726 shares of the company’s stock after selling 723 shares […] - 2025-07-21 05:51:00
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Holdings Lowered by Teacher Retirement System of Texas: Teacher Retirement System of Texas trimmed its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 8.2% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 12,025 shares of the company’s stock after selling 1,074 shares during the period. Teacher Retirement System […] - 2025-07-16 04:34:43
Amalgamated Bank Sells 467 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Amalgamated Bank cut its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 2.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 16,938 shares of the company’s stock after selling 467 shares during the quarter. Amalgamated Bank’s holdings […] - 2025-07-10 05:10:51
GAMMA Investing LLC Has $58,000 Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX): GAMMA Investing LLC grew its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 153.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,203 shares of the company’s stock after buying an additional 728 shares during the period. GAMMA Investing […] - 2025-07-10 04:14:49
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Recommendation of “Buy” from Analysts: Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) has been assigned a consensus recommendation of “Buy” from the ten brokerages that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the […] - 2025-07-09 04:43:49
Oregon Public Employees Retirement Fund Has $663,000 Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Oregon Public Employees Retirement Fund cut its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 2.1% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 13,700 shares of the company’s stock after selling 300 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in […] - 2025-07-08 05:24:51
Illinois Municipal Retirement Fund Sells 14,000 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Illinois Municipal Retirement Fund cut its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 41.8% in the 1st quarter, Holdings Channel.com reports. The fund owned 19,509 shares of the company’s stock after selling 14,000 shares during the period. Illinois Municipal Retirement Fund’s holdings in Protagonist Therapeutics were worth $943,000 as of […] - 2025-07-02 05:28:54
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by California State Teachers Retirement System: California State Teachers Retirement System cut its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 0.7% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 42,349 shares of the company’s stock after selling 316 shares during the quarter. California State Teachers Retirement System’s holdings in Protagonist Therapeutics were worth […] - 2025-06-09 05:00:56
Tidal Investments LLC Decreases Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Tidal Investments LLC trimmed its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 4.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 21,012 shares of the company’s stock after selling 1,050 shares during the period. Tidal Investments LLC’s holdings in Protagonist Therapeutics were worth $811,000 at the end of the most […] - 2025-05-27 05:22:57
Brokerages Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Target Price at $65.44: Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) have been given an average recommendation of “Buy” by the nine research firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to […] - 2025-05-23 03:14:53
Protagonist Therapeutics (NASDAQ:PTGX) Earns “Buy” Rating from HC Wainwright: Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report released on Monday,Benzinga reports. They presently have a $80.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 71.64% from the stock’s previous close. Other equities research analysts […] - 2025-05-21 03:03:18
Deutsche Bank AG Acquires 17,763 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Deutsche Bank AG increased its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 14.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 137,932 shares of the company’s stock after purchasing an additional 17,763 shares during […] - 2025-05-19 05:10:57
Comerica Bank Trims Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Comerica Bank decreased its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 1.7% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 20,558 shares of the company’s stock after selling 346 shares during the period. Comerica Bank’s holdings in Protagonist Therapeutics were worth $794,000 at the end of the most […] - 2025-05-14 05:20:53
Marshall Wace LLP Lowers Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Marshall Wace LLP trimmed its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 93.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,716 shares of the company’s stock after selling 295,657 shares during the quarter. […] - 2025-05-02 05:30:50
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by Mariner LLC: Mariner LLC increased its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 12.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 17,983 shares of the company’s stock after buying an additional 2,004 shares during the period. Mariner LLC’s holdings in Protagonist Therapeutics were worth […] - 2025-04-30 05:19:01
Analysts Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Target Price at $65.44: Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) have earned a consensus recommendation of “Buy” from the nine research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation […] - 2025-04-28 02:22:54
Barclays PLC Decreases Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Barclays PLC reduced its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 0.2% during the 4th quarter, Holdings Channel.com reports. The firm owned 126,733 shares of the company’s stock after selling 262 shares during the period. Barclays PLC’s holdings in Protagonist Therapeutics were worth $4,891,000 as of its most recent SEC filing. A […] - 2025-04-27 05:24:54
Bank of Montreal Can Boosts Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Bank of Montreal Can grew its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 4.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 6,250 shares of the company’s stock after acquiring an additional 270 shares during the quarter. Bank of Montreal Can’s holdings in Protagonist Therapeutics were worth $241,000 […] - 2025-04-25 04:36:55
Geode Capital Management LLC Acquires 2,366 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Geode Capital Management LLC raised its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 0.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,377,063 shares of the company’s stock after purchasing an additional 2,366 shares during the quarter. […] - 2025-04-14 05:00:52

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) PTGX holdings

Date	Number of PTGX Shares Held	Base Market Value of PTGX Shares	Local Market Value of PTGX Shares	Change in PTGX Shares Held	Change in PTGX Base Value	Current Price per PTGX Share Held	Previous Price per PTGX Share Held
2026-01-15 (Thursday)	42,864	USD 3,632,724	USD 3,632,724	194	USD -4,040	USD 84.75	USD 85.23
2026-01-14 (Wednesday)	42,670	USD 3,636,764	USD 3,636,764	194	USD 180,917	USD 85.23	USD 81.36
2026-01-13 (Tuesday)	42,476	USD 3,455,847	USD 3,455,847	0	USD 47,148	USD 81.36	USD 80.25
2026-01-12 (Monday)	42,476	USD 3,408,699	USD 3,408,699	194	USD 16,837	USD 80.25	USD 80.22
2026-01-09 (Friday)	42,282	USD 3,391,862	USD 3,391,862	291	USD 24,184	USD 80.22	USD 80.2
2026-01-08 (Thursday)	41,991	USD 3,367,678	USD 3,367,678	0	USD -89,861	USD 80.2	USD 82.34
2026-01-07 (Wednesday)	41,991	USD 3,457,539	USD 3,457,539	194	USD 18,900	USD 82.34	USD 82.27
2026-01-06 (Tuesday)	41,797	USD 3,438,639	USD 3,438,639	0	USD -79,832	USD 82.27	USD 84.18
2026-01-05 (Monday)	41,797	USD 3,518,471	USD 3,518,471	0	USD -125,391	USD 84.18	USD 87.18
2026-01-02 (Friday)	41,797	USD 3,643,862	USD 3,643,862	97	USD 1,784	USD 87.18	USD 87.34
2025-12-31 (Wednesday)	41,700	USD 3,642,078	USD 3,642,078	0	USD 3,336	USD 87.34	USD 87.26

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of PTGX by Blackrock for IE00BDZVHG35

Show aggregate share trades of PTGX

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2026-01-15 BUY 194 87.430 84.330 84.640 USD 16,420 57.29
2026-01-14 BUY 194 85.290 80.470 80.952 USD 15,705 57.17
2026-01-12 BUY 194 81.090 78.750 78.984 USD 15,323 56.96
2026-01-09 BUY 291 81.400 79.380 79.582 USD 23,158 56.86
2026-01-07 BUY 194 82.690 79.180 79.531 USD 15,429 56.65
2026-01-02 BUY 97 88.155 85.190 85.487 USD 8,292 56.27
2025-12-30 BUY 97 88.315 86.130 86.348 USD 8,376 55.99
2025-12-23 SELL -1,164 89.790 87.270 87.522 USD -101,876 55.39 Loss of -37,402 on sale
2025-12-19 SELL -3,354 87.530 84.810 85.082 USD -285,365 55.10 Loss of -100,566 on sale
2025-12-17 SELL -525 92.540 88.380 88.796 USD -46,618 54.79 Loss of -17,851 on sale
2025-12-16 SELL -105 94.540 90.180 90.616 USD -9,515 54.62 Loss of -3,780 on sale
2025-12-15 BUY 210 96.540 94.170 94.407 USD 19,825 54.43
2025-12-11 BUY 707 93.070 91.070 91.270 USD 64,528 54.05
2025-12-04 BUY 2,080 88.100 85.130 85.427 USD 177,688 53.19
2025-12-02 BUY 1,560 86.390 83.520 83.807 USD 130,739 52.87
2025-11-28 BUY 104 90.460 88.780 88.948 USD 9,251 52.52
2025-11-26 BUY 312 90.850 89.500 89.635 USD 27,966 52.14
2025-11-26 BUY 312 90.850 89.500 89.635 USD 27,966 52.14
2025-11-25 BUY 520 89.880 87.760 87.972 USD 45,745 51.95
2025-11-24 BUY 104 88.335 85.745 86.004 USD 8,944 51.76
2025-11-20 SELL -416 86.950 83.995 84.291 USD -35,065 51.42 Loss of -13,673 on sale
2025-11-19 BUY 104 86.645 84.450 84.669 USD 8,806 51.25
2025-11-18 BUY 624 86.360 83.790 84.047 USD 52,445 51.08
2025-11-17 BUY 208 85.450 82.790 83.056 USD 17,276 50.90
2025-11-14 BUY 104 85.900 82.060 82.444 USD 8,574 50.72
2025-11-12 BUY 104 86.900 84.500 84.740 USD 8,813 50.37
2025-11-10 BUY 103 84.840 79.560 80.088 USD 8,249 50.00
2025-11-06 BUY 103 79.920 77.000 77.292 USD 7,961 49.68
2025-11-04 BUY 104 78.010 75.440 75.697 USD 7,872 49.38
2025-10-30 BUY 520 78.740 76.750 76.949 USD 40,013 48.91
2025-10-29 BUY 208 76.690 79.000 78.769 USD 16,384 48.75
2025-10-22 SELL -416 73.500 74.950 74.805 USD -31,119 47.99 Loss of -11,157 on sale
2025-10-20 BUY 208 76.720 77.660 77.566 USD 16,134 47.66
2025-10-17 BUY 519 77.500 77.580 77.572 USD 40,260 47.48
2025-10-15 BUY 824 77.680 78.150 78.103 USD 64,357 47.31
2025-10-03 BUY 714 64.830 65.380 65.325 USD 46,642 47.02
2025-10-02 BUY 102 64.980 65.500 65.448 USD 6,676 46.91
2025-09-30 BUY 204 66.430 67.040 66.979 USD 13,664 46.69
2025-09-26 BUY 204 67.420 68.260 68.176 USD 13,908 46.45
2025-09-25 BUY 204 64.700 66.380 66.212 USD 13,507 46.34
2025-09-18 BUY 107 62.140 62.210 62.203 USD 6,656 46.24
2025-09-17 BUY 324 59.220 61.335 61.123 USD 19,804 46.16
2025-07-17 SELL -214 56.440 57.726 57.597 USD -12,326 45.89 Loss of -2,505 on sale
2025-07-16 BUY 502 56.640 57.360 57.288 USD 28,759 45.82
2025-07-11 SELL -848 53.000 53.765 53.688 USD -45,528 45.65 Loss of -6,818 on sale
2025-07-02 BUY 5,830 50.690 52.024 51.891 USD 302,522 45.48
2025-06-25 BUY 212 54.440 54.955 54.904 USD 11,640 45.21
2025-06-20 BUY 1,181 53.340 54.970 54.807 USD 64,727 45.04
2025-06-11 BUY 204 55.340 56.830 56.681 USD 11,563 44.51
2025-06-10 BUY 204 56.370 57.700 57.567 USD 11,744 44.42
2025-06-04 SELL -102 51.530 51.710 51.692 USD -5,273 44.12 Loss of -772 on sale
2025-04-23 BUY 102 46.160 47.345 47.227 USD 4,817 43.71
2025-04-10 SELL -816 40.890 43.000 42.789 USD -34,916 43.57 Profit of 640 on sale
2025-04-08 SELL -102 41.670 45.880 45.459 USD -4,637 43.61 Loss of -189 on sale
2025-04-07 SELL -102 43.210 45.320 45.109 USD -4,601 43.61 Loss of -153 on sale
2025-04-04 SELL -510 44.440 46.450 46.249 USD -23,587 43.60 Loss of -1,350 on sale
2025-04-01 BUY 893 46.880 48.680 48.500 USD 43,311 43.51
2025-03-31 SELL -300 48.360 48.800 48.756 USD -14,627 43.45 Loss of -1,593 on sale
2025-03-21 BUY 2,149 52.650 53.230 53.172 USD 114,267 42.88
2025-03-14 SELL -1,488 54.780 55.390 55.329 USD -82,330 42.10 Loss of -19,689 on sale
2025-03-07 SELL -188 38.350 39.900 39.745 USD -7,472 41.25 Profit of 282 on sale
2025-03-04 SELL -94 38.660 39.700 39.596 USD -3,722 41.37 Profit of 166 on sale
2025-02-25 BUY 188 35.090 36.820 36.647 USD 6,890 41.77
2025-02-19 SELL -94 38.530 38.645 38.634 USD -3,632 42.05 Profit of 321 on sale
2025-02-13 BUY 279 38.680 38.720 38.716 USD 10,802 42.34
2025-02-12 BUY 93 37.420 37.540 37.528 USD 3,490 42.44
2025-02-11 BUY 372 36.990 38.010 37.908 USD 14,102 42.55
2024-12-30 SELL -2,786 38.510 38.850 38.816 USD -108,141 44.55 Profit of 15,972 on sale
2024-11-18 SELL -1,515 40.390 41.050 40.984 USD -62,091 46.71 Profit of 8,671 on sale
2024-11-08 SELL -101 46.230 48.860 48.597 USD -4,908 46.99 Loss of -162 on sale
2024-10-21 SELL -101 45.960 47.030 46.923 USD -4,739 0.00 Loss of -4,739 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2026-01-15	BUY	194	87.430	84.330	84.640	USD 16,420	57.29
2026-01-14	BUY	194	85.290	80.470	80.952	USD 15,705	57.17
2026-01-12	BUY	194	81.090	78.750	78.984	USD 15,323	56.96
2026-01-09	BUY	291	81.400	79.380	79.582	USD 23,158	56.86
2026-01-07	BUY	194	82.690	79.180	79.531	USD 15,429	56.65
2026-01-02	BUY	97	88.155	85.190	85.487	USD 8,292	56.27
2025-12-30	BUY	97	88.315	86.130	86.348	USD 8,376	55.99
2025-12-23	SELL	-1,164	89.790	87.270	87.522	USD -101,876	55.39 Loss of -37,402 on sale
2025-12-19	SELL	-3,354	87.530	84.810	85.082	USD -285,365	55.10 Loss of -100,566 on sale
2025-12-17	SELL	-525	92.540	88.380	88.796	USD -46,618	54.79 Loss of -17,851 on sale
2025-12-16	SELL	-105	94.540	90.180	90.616	USD -9,515	54.62 Loss of -3,780 on sale
2025-12-15	BUY	210	96.540	94.170	94.407	USD 19,825	54.43
2025-12-11	BUY	707	93.070	91.070	91.270	USD 64,528	54.05
2025-12-04	BUY	2,080	88.100	85.130	85.427	USD 177,688	53.19
2025-12-02	BUY	1,560	86.390	83.520	83.807	USD 130,739	52.87
2025-11-28	BUY	104	90.460	88.780	88.948	USD 9,251	52.52
2025-11-26	BUY	312	90.850	89.500	89.635	USD 27,966	52.14
2025-11-26	BUY	312	90.850	89.500	89.635	USD 27,966	52.14
2025-11-25	BUY	520	89.880	87.760	87.972	USD 45,745	51.95
2025-11-24	BUY	104	88.335	85.745	86.004	USD 8,944	51.76
2025-11-20	SELL	-416	86.950	83.995	84.291	USD -35,065	51.42 Loss of -13,673 on sale
2025-11-19	BUY	104	86.645	84.450	84.669	USD 8,806	51.25
2025-11-18	BUY	624	86.360	83.790	84.047	USD 52,445	51.08
2025-11-17	BUY	208	85.450	82.790	83.056	USD 17,276	50.90
2025-11-14	BUY	104	85.900	82.060	82.444	USD 8,574	50.72
2025-11-12	BUY	104	86.900	84.500	84.740	USD 8,813	50.37
2025-11-10	BUY	103	84.840	79.560	80.088	USD 8,249	50.00
2025-11-06	BUY	103	79.920	77.000	77.292	USD 7,961	49.68
2025-11-04	BUY	104	78.010	75.440	75.697	USD 7,872	49.38
2025-10-30	BUY	520	78.740	76.750	76.949	USD 40,013	48.91
2025-10-29	BUY	208	76.690	79.000	78.769	USD 16,384	48.75
2025-10-22	SELL	-416	73.500	74.950	74.805	USD -31,119	47.99 Loss of -11,157 on sale
2025-10-20	BUY	208	76.720	77.660	77.566	USD 16,134	47.66
2025-10-17	BUY	519	77.500	77.580	77.572	USD 40,260	47.48
2025-10-15	BUY	824	77.680	78.150	78.103	USD 64,357	47.31
2025-10-03	BUY	714	64.830	65.380	65.325	USD 46,642	47.02
2025-10-02	BUY	102	64.980	65.500	65.448	USD 6,676	46.91
2025-09-30	BUY	204	66.430	67.040	66.979	USD 13,664	46.69
2025-09-26	BUY	204	67.420	68.260	68.176	USD 13,908	46.45
2025-09-25	BUY	204	64.700	66.380	66.212	USD 13,507	46.34
2025-09-18	BUY	107	62.140	62.210	62.203	USD 6,656	46.24
2025-09-17	BUY	324	59.220	61.335	61.123	USD 19,804	46.16
2025-07-17	SELL	-214	56.440	57.726	57.597	USD -12,326	45.89 Loss of -2,505 on sale
2025-07-16	BUY	502	56.640	57.360	57.288	USD 28,759	45.82
2025-07-11	SELL	-848	53.000	53.765	53.688	USD -45,528	45.65 Loss of -6,818 on sale
2025-07-02	BUY	5,830	50.690	52.024	51.891	USD 302,522	45.48
2025-06-25	BUY	212	54.440	54.955	54.904	USD 11,640	45.21
2025-06-20	BUY	1,181	53.340	54.970	54.807	USD 64,727	45.04
2025-06-11	BUY	204	55.340	56.830	56.681	USD 11,563	44.51
2025-06-10	BUY	204	56.370	57.700	57.567	USD 11,744	44.42
2025-06-04	SELL	-102	51.530	51.710	51.692	USD -5,273	44.12 Loss of -772 on sale
2025-04-23	BUY	102	46.160	47.345	47.227	USD 4,817	43.71
2025-04-10	SELL	-816	40.890	43.000	42.789	USD -34,916	43.57 Profit of 640 on sale
2025-04-08	SELL	-102	41.670	45.880	45.459	USD -4,637	43.61 Loss of -189 on sale
2025-04-07	SELL	-102	43.210	45.320	45.109	USD -4,601	43.61 Loss of -153 on sale
2025-04-04	SELL	-510	44.440	46.450	46.249	USD -23,587	43.60 Loss of -1,350 on sale
2025-04-01	BUY	893	46.880	48.680	48.500	USD 43,311	43.51
2025-03-31	SELL	-300	48.360	48.800	48.756	USD -14,627	43.45 Loss of -1,593 on sale
2025-03-21	BUY	2,149	52.650	53.230	53.172	USD 114,267	42.88
2025-03-14	SELL	-1,488	54.780	55.390	55.329	USD -82,330	42.10 Loss of -19,689 on sale
2025-03-07	SELL	-188	38.350	39.900	39.745	USD -7,472	41.25 Profit of 282 on sale
2025-03-04	SELL	-94	38.660	39.700	39.596	USD -3,722	41.37 Profit of 166 on sale
2025-02-25	BUY	188	35.090	36.820	36.647	USD 6,890	41.77
2025-02-19	SELL	-94	38.530	38.645	38.634	USD -3,632	42.05 Profit of 321 on sale
2025-02-13	BUY	279	38.680	38.720	38.716	USD 10,802	42.34
2025-02-12	BUY	93	37.420	37.540	37.528	USD 3,490	42.44
2025-02-11	BUY	372	36.990	38.010	37.908	USD 14,102	42.55
2024-12-30	SELL	-2,786	38.510	38.850	38.816	USD -108,141	44.55 Profit of 15,972 on sale
2024-11-18	SELL	-1,515	40.390	41.050	40.984	USD -62,091	46.71 Profit of 8,671 on sale
2024-11-08	SELL	-101	46.230	48.860	48.597	USD -4,908	46.99 Loss of -162 on sale
2024-10-21	SELL	-101	45.960	47.030	46.923	USD -4,739	0.00 Loss of -4,739 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of PTGX

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	204,101	2,581	524,512	38.9%
2025-09-18	261,238	603	538,967	48.5%
2025-09-17	160,871	455	278,662	57.7%
2025-09-16	119,487	213	179,491	66.6%
2025-09-15	164,481	90	265,275	62.0%
2025-09-12	129,277	1,000	230,328	56.1%
2025-09-11	242,764	0	391,638	62.0%
2025-09-10	158,669	1,425	254,846	62.3%
2025-09-09	425,476	500	622,218	68.4%
2025-09-08	528,123	800	611,363	86.4%
2025-09-05	518,633	11,824	804,839	64.4%
2025-09-04	337,385	2,916	576,292	58.5%
2025-09-03	195,570	1,053	372,182	52.5%
2025-09-02	188,399	0	271,348	69.4%
2025-08-29	165,571	500	265,840	62.3%
2025-08-28	272,112	902	423,847	64.2%
2025-08-27	322,274	11,729	514,925	62.6%
2025-08-26	67,797	3	206,573	32.8%
2025-08-25	108,118	1,807	147,926	73.1%
2025-08-22	92,580	0	136,504	67.8%
2025-08-21	67,903	732	226,490	30.0%
2025-08-20	137,747	4,436	275,169	50.1%
2025-08-19	108,591	2,229	172,546	62.9%
2025-08-18	145,066	89	190,752	76.0%
2025-08-15	102,863	1,000	136,937	75.1%
2025-08-14	166,263	0	194,337	85.6%
2025-08-13	142,989	4,887	265,978	53.8%
2025-08-12	119,666	1,400	138,812	86.2%
2025-08-11	161,809	0	224,270	72.1%
2025-08-08	126,345	380	200,061	63.2%
2025-08-07	250,926	10	327,014	76.7%
2025-08-06	118,632	274	136,885	86.7%
2025-08-05	95,352	5	128,071	74.5%
2025-08-04	107,663	3,147	140,665	76.5%
2025-08-01	102,643	0	185,382	55.4%
2025-07-31	134,674	26,403	236,093	57.0%
2025-07-30	88,986	1,477	128,497	69.3%
2025-07-29	108,417	242	253,165	42.8%
2025-07-28	195,264	19	241,347	80.9%
2025-07-25	117,334	156	198,470	59.1%
2025-07-24	191,250	125	255,624	74.8%
2025-07-23	393,783	53	542,672	72.6%
2025-07-22	117,379	20,048	158,451	74.1%
2025-07-21	92,245	93	135,809	67.9%
2025-07-18	93,308	98	145,564	64.1%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE